Person
Peter Fedichev
Longevity scientist and biotechnology entrepreneur investigating physiological resilience and mathematical models of aging.
Stories on Angle
Background
Selected excerpts from Wikipedia. This is general background, not Angle's reporting, and it may have changed since the stories above were published.
Peter Fedichev is a physicist and biotechnologist. He worked on ultracold quantum systems before moving into computational drug design and later longevity research.
He is the co-founder and chief executive officer of Gero, a biotechnology company based in Singapore that applies physics-based and machine-learning methods to ageing and disease research.
Education and early career
Fedichev received an M.Sc. in theoretical physics from the Moscow Institute of Physics and Technology while conducting research at the Kurchatov Institute. In 1994 he joined the University of Amsterdam and the AMOLF institute, completing a Ph.D. cum laude in theoretical physics. He later worked at the University of Innsbruck on condensed matter and quantum-gas systems.
Research
Following his doctoral studies at the University of Amsterdam and AMOLF, Fedichev worked in the field of ultracold atomic gases, Bose-Einstein condensates, quantum information, and many-body quantum systems. During the late 1990s and early 2000s he collaborated with physicists including Peter Zoller, J. Ignacio Cirac, Jan von Delft, Uwe R. Fischer, and Andrew Daley on problems in quantum simulation, strongly correlated quantum matter, and analogue models of gravitational phenomena.
His research contributed to several areas of quantum physics, including anyonic excitations in ultracold gases, spin-charge separation, quantum information processing, and analogue gravity.
Several of these publications became highly cited within the quantum-gas and quantum-simulation communities. His paper "Influence of Nearly Resonant Light on the Scattering Length in Low-Temperature Atomic Gases" is among the early theoretical works on optical control of atomic interactions in ultracold gases.
Some of Fedichev's collaborators, including Peter Zoller and J. Ignacio Cirac, later received the 2022 Wolf Prize in Physics for foundational contributions to quantum information science and quantum simulation. Their work has frequently been discussed as laying foundations for modern quantum computing and quantum simulation technologies.
In the early 2000s, Fedichev moved from theoretical physics into computational chemistry and drug discovery and co-founded Quantum Pharmaceuticals, an early company exploring computational drug design. This work applied physics-based computational modeling to molecular simulation, biomolecular electrostatics, virtual screening, and structure-based drug design, including antiviral and metabolism-related drug discovery programs.
Fedichev and collaborators reported the discovery of small-molecule antiviral compounds targeting influenza A nucleoprotein and the HIV-1 matrix protein.
This work resulted in a series of intellectual property filings. Fedichev is listed as an inventor on U.S. Patent 9,610,264, "Compounds for the Treatment and Prevention of Retroviral Infections", granted in 2017. …
From the Wikipedia article Peter Fedichev (revision of ). Wikipedia contributors; selected plain-text excerpts from this revision. Formatting, reference markers and non-prose material removed. Available under Creative Commons Attribution-Share Alike 4.0. Identity from Wikidata (CC0).